title: [Intensive chemotherapy with autologous stem cell transplantation in ovarian cancers: analysis of 67 patients treated at the Paoli-Calmettes Institute and a review of the literature].
abstract: Despite important initial chemosensitivity, advanced ovarian cancer has a bad prognosis with a median survival of 20 to 30 months. These results might be better with intensive chemotherapy. We analysed 67 patients treated by intensive chemotherapy with autologous stem cell transplantation for advanced ovarian cancer at Institute Paoli-Calmettes between 1980 and 1994. Population was divided in two groups: salvage group (n = 30) for initial chemotherapy-refractory patients and consolidation group (n = 37) for sensitive patients. Several successive conditioning regimens were used, all based on alkylating agents. Principal toxicities were severe aplasia and mucositis. Four patients died from toxicity related to infection during strong immunosuppression. In salvage group, 9 out of 21 evaluable patients responded (43%), but duration of responses was short (median range of 5 months) and 2-year overall survival rate was 8% after transplantation. In consolidation group, 19 patients are alive and 15 are without disease progression with a median follow-up of 42 months (17, 161) after diagnosis. Five-year disease-free survival rate is 28% (median range of 35 months) and 5-year overall survival rate is 48% (median range of 41 months). Intensification does not seem to be long term beneficial for initial chemotherapy refractory patients, despite objective responses rate better than classical treatment. On the other hand, results seem better than conventional treatments in case of chemosensitive disease and should be confirmed prospectively in larger cohort of patients. Moreover, other research directions are open like intensification supported by hematopoietic growth-factors and peripheral stem cells, definition of best conditioning regimen, use of taxanes, and intensification in first line chemotherapy after initial surgery.
authors.affiliation: Département d'oncologie médicale, institut Paoli-Calmettes, Marseille.
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: F
authors.initials: F
authors.lastname: Bertucci
authors.forename: G
authors.initials: G
authors.lastname: Gravis
authors.forename: J
authors.initials: J
authors.lastname: Camerlo
authors.forename: D
authors.initials: D
authors.lastname: Cowen
authors.forename: J R
authors.initials: JR
authors.lastname: Delpero
authors.forename: M
authors.initials: M
authors.lastname: Conte
authors.forename: J
authors.initials: J
authors.lastname: Jacquemier
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: V J
authors.initials: VJ
authors.lastname: Bardou
authors.forename: C
authors.initials: C
authors.lastname: Chabannon
authors.forename: A P
authors.initials: AP
authors.lastname: Blanc
authors.forename: D
authors.initials: D
authors.lastname: Jaubert
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome